These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12086497)

  • 21. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
    Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
    Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors.
    Kadam RU; Roy N
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5136-43. PubMed ID: 16879960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
    McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
    Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor.
    Mochalkin I; Knafels JD; Lightle S
    Protein Sci; 2008 Mar; 17(3):450-7. PubMed ID: 18287278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety.
    Cohen F; Aggen JB; Andrews LD; Assar Z; Boggs J; Choi T; Dozzo P; Easterday AN; Haglund CM; Hildebrandt DJ; Holt MC; Joly K; Jubb A; Kamal Z; Kane TR; Konradi AW; Krause KM; Linsell MS; Machajewski TD; Miroshnikova O; Moser HE; Nieto V; Phan T; Plato C; Serio AW; Seroogy J; Shakhmin A; Stein AJ; Sun AD; Sviridov S; Wang Z; Wlasichuk K; Yang W; Zhou X; Zhu H; Cirz RT
    ChemMedChem; 2019 Aug; 14(16):1560-1572. PubMed ID: 31283109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
    Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
    Barb AW; Zhou P
    Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
    Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Pseudomonas aeruginosa deacetylase LpxC inhibitory activity of dual PDE4-TNFalpha inhibitors: a multiscreening approach.
    Kadam RU; Garg D; Chavan A; Roy N
    J Chem Inf Model; 2007; 47(3):1188-95. PubMed ID: 17458951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent LpxC Inhibitors with
    Krause KM; Haglund CM; Hebner C; Serio AW; Lee G; Nieto V; Cohen F; Kane TR; Machajewski TD; Hildebrandt D; Pillar C; Thwaites M; Hall D; Miesel L; Hackel M; Burek A; Andrews LD; Armstrong E; Swem L; Jubb A; Cirz RT
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway.
    Hyland SA; Eveland SS; Anderson MS
    J Bacteriol; 1997 Mar; 179(6):2029-37. PubMed ID: 9068651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
    Miller MD; Gao N; Ross PL; Olivier NB
    Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LpxC inhibitors: a patent review (2010-2016).
    Kalinin DV; Holl R
    Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-step synthesis of oxazoline and dihydrooxazine libraries.
    Chaudhry P; Schoenen F; Neuenswander B; Lushington GH; Aubé J
    J Comb Chem; 2007; 9(3):473-6. PubMed ID: 17391008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.